The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer-Reference-Cited by-同舟云学术

The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer

Published:2018-06 Issue:3 Volume:16 Page:e645-e653
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Iacovelli Roberto,Ciccarese Chiara,Bria Emilio,Romano Mario,Fantinel Emanuela,Bimbatti Davide,Muraglia Alessandro,Porcaro Antonio Benito,Siracusano Salvatore,Brunelli Matteo,Mazzarotto Renzo,Artibani Walter,Tortora Giampaolo

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference24 articles.

1. Cancer Statistics, 2017;Siegel;CA Cancer J Clin,2017

2. Adverse effects of androgen deprivation therapy and strategies to mitigate them;Nguyen;Eur Urol,2015

3. Changes in body composition during androgen deprivation therapy for prostate cancer;Smith;J Clin Endocrinol Metab,2002

4. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer;Smith;Urology,2004

5. Insulin sensitivity during combined androgen blockade for prostate cancer;Smith;J Clin Endocrinol Metab,2006

Cited by 129 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Associations between glucocorticoid use and major adverse cardiovascular events in patients with prostate cancer receiving antiandrogen: a retrospective cohort study;Prostate Cancer and Prostatic Diseases;2024-09-10

2. Metastasis-Free Survival Versus Treatment-Free Survival in Biochemically Recurrent Prostate Cancer: The EMBARK Trial;Journal of Clinical Oncology;2024-08-20

3. Abiraterone or Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer;JAMA Network Open;2024-08-16

4. Assessment of Cardiovascular Events Caused by New-Generation Androgen Receptor Pathway Inhibitors Used for Prostate Cancer: A Real-World Study in Japan;Oncology;2024-08-14

5. Intercellular pathways of cancer treatment-related cardiotoxicity and their therapeutic implications: the paradigm of radiotherapy;Pharmacology & Therapeutics;2024-08